Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Moti L. Kashyap
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis and Vasculopathy in a Rat Model of Chronic Kidney Disease
Journal of Cardiac Failure
Cardiovascular Medicine
Cardiology
Mechanism of Nicotinic Acid Transport in Human Liver Cells: Experiments With HepG2 Cells and Primary Hepatocytes
American Journal of Physiology - Cell Physiology
Physiology
Cell Biology
Related publications
Single Therapeutic and Supratherapeutic Doses of Sacubitril/Valsartan (LCZ696) Do Not Affect Cardiac Repolarization
European Journal of Clinical Pharmacology
Medicine
Pharmacology
Transition From Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Ii-Receptor-Blocker to Sacubitril/Valsartan in Chronic Heart Failure Patients: Initial Experiences in Clinical Practice
Cor et Vasa
Cardiovascular Medicine
Cardiology
Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
Journal of the American Heart Association
Cardiovascular Medicine
Cardiology
Angiotensin-(1-9) Attenuates Cardiac Fibrosis in the Stroke-Prone Spontaneously Hypertensive Rat via the Angiotensin Type 2 Receptor
Hypertension
Internal Medicine
Placental Extract Suppresses Cardiac Hypertrophy and Fibrosis in an Angiotensin II-induced Cachexia Model in Mice
Heliyon
Multidisciplinary
Sex Differences in the Response to Angiotensin II Receptor Blockade in a Rat Model of Eccentric Cardiac Hypertrophy
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
Chronic Administration of Hexarelin Attenuates Cardiac Fibrosis in the Spontaneously Hypertensive Rat
American Journal of Physiology - Heart and Circulatory Physiology
Cardiovascular Medicine
Physiology
Cardiology
Electronegative LDL-mediated Cardiac Electrical Remodeling in a Rat Model of Chronic Kidney Disease
Scientific Reports
Multidisciplinary
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure
Journal of the American Heart Association
Cardiovascular Medicine
Cardiology